title: [Drug therapy of urethral diseases].
abstract: OBJECTIVE
  To describe drugs targeting urethra and prostate to treat dysfunctions such LUTS related to BPH, primary bladder neck obstruction (PBNO), detrusor sphincter dyssynergia (DSD) or sphincter deficiency (SD).
  
  
  METHODS
  Pubmed search for efficacy, mode of action and side effects for each molecule. Additional data were searched from the French regulatory agencies web sites (HAS and ANSM).
  
  
  RESULTS
  To treat LUTS related to BPH alpha-blockers (AB) and 5-alpha reductase inhibitors (5ARIs) have a clearer efficacy than plant extract. Daily Phosphodiesterase 5 inhibitors (PDE5Is) alone or in association with AB also demonstrate efficacy in this indication. AB are an option in PBNO and DSD related to multiple sclerosis. Although Botulinum toxin A derived molecules decrease urethral pressure in patient with DSD related to spinal cord injury or multiple sclerosis, efficiency remains to be demonstrated. Duloxetine a serotonin reuptake inhibitor increases urethral sphincter pressure and reduce stress urinary incontinence in women and men. Nevertheless, moderate efficacy combine with frequent side effects lead French regulation agency to reject its agreement.
  
  
  CONCLUSIONS
  Armamenterium to treat urethral dysfunctions has recently increases. Two new therapeutic classes emerge: PDE5Is to treat LUTS related to BPH and an SRIs (Duloxetine) to treat stress urinary incontinence. Efficacy and safety evaluation of all the possible associations between drugs targeting urethra and/or bladder is needed to a subtler and more efficient pharmacologic modulation of lower urinary tract dysfunction.
authors.affiliation: Département d'urologie, transplantation rénale et andrologie, CHU Rangueil, TSA 50032, 31059 Toulouse, France.
authors.forename: X
authors.initials: X
authors.lastname: Game
authors.forename: J-N
authors.initials: JN
authors.lastname: Cornu
authors.forename: G
authors.initials: G
authors.lastname: Robert
authors.forename: A
authors.initials: A
authors.lastname: Descazeaud
authors.forename: S
authors.initials: S
authors.lastname: Droupy
authors.forename: A
authors.initials: A
authors.lastname: Benard-Laribiere
authors.forename: C
authors.initials: C
authors.lastname: Bastide
authors.forename: L
authors.initials: L
authors.lastname: Guy
authors.forename: F
authors.initials: F
authors.lastname: Bruyére
authors.forename: G
authors.initials: G
authors.lastname: Karsenty
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000726:Androgen Antagonists / Q000627:therapeutic use; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D005233:Fatty Alcohols / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009465:Neuromuscular Agents / Q000627:therapeutic use; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D000068218:Prunus africana; D028024:Serenoa; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D014522:Urethral Diseases / Q000188:drug therapy*
chemical_list: D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D000726:Androgen Antagonists; D019274:Botulinum Toxins, Type A; D005233:Fatty Alcohols; D009465:Neuromuscular Agents; D058986:Phosphodiesterase 5 Inhibitors; D010936:Plant Extracts; D017367:Selective Serotonin Reuptake Inhibitors; C009375:Tadenan; C040972:saw palmetto extract
keywords: 5-alpha reductase inhibitors; Alpha-blockers; Alpha-bloquant; Botulinum toxin; Duloxetine benign prostatic hyperplasia; Duloxétine hypertrophie bénigne de la prostate; Extrait de plante; Incontinence urinaire; Inhibiteur des 5-alpha réductases; Inhibiteur des phosphodiestérases 5; Phosphodiesterase 5 inhibitors; Plant extract; Toxine botulinique; Urethra; Urinary incontinence; Urètre